Novel Medicinal Chemicals: Cardiomyogenesis from Human Stem Cells

新型药用化学品：人类干细胞的心肌发生

• 批准号: 8058646
• 负责人: John R Cashman
• 金额: $ 17.25万
• 依托单位: CHEMREGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-04 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8058646
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Address; Age; Age-Years; American; American Heart Association; Area; Biological Assay; Biology; Biotechnology; Cardiac; Cardiac Myocytes; Cell Differentiation process; Cell Line; Cell physiology; Cells; Cellular Assay; Chemicals; Colony-Forming Units Assay; Data; Defibrillators; Development; Devices; Differentiation Inducer; Direct Costs; Disease; Drug Interactions; Facilities and Administrative Costs; Failure; Goals; Heart; Heart Diseases; Heart Injuries; Heart Transplantation; Heart failure; Heart-Assist Devices; Hospitalization; Housing; Human; Immunosuppressive Agents; Implant; In Vitro; Incidence; Individual; Industry; Lead; Libraries; Maps; Modification; Morbidity - disease rate; Mus; Myocardial Infarction; Myocardium; Natural regeneration; Pacemakers; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Population; Preparation; Process; Production; Pump; Reagent; Regenerative Medicine; Research; Societies; Source; Staging; Stem Cell Research; Stem cells; Structure-Activity Relationship; Testing; Therapeutic; Therapeutic Human Experimentation; Tissues; Transplant Recipients; Transplantation; United States; Western World; Work; analog; attack victim; base; cardiogenesis; commercialization; cost; economic cost; embryonic stem cell; heart function; human embryonic stem cell; human stem cells; implantation; improved; induced pluripotent stem cell; injured; member; novel; productivity loss; research study; safety testing; small molecule; stem; stem cell differentiation; stem cell therapy; tool

DESCRIPTION (provided by applicant): Over 1-2% of Americans greater than 65 years of age have heart disease. According to the American Heart Association, heart failure is one of the most common causes of hospitalization for patients over 65 years of age in the Western world and as the population ages, this situation will only get worse. Currently, more than 5 million Americans suffer from heart failure. In 2009, the economic cost (direct and indirect) to US society for heart disease was in excess of $37 billion per year. Certain diseases related to heart muscle failure or heart muscle weakening are treatable with drugs or devices such as defibrillators, pacemakers or implanted pumps. However, in heart attacks, when heart muscle cells die, transplantation becomes the only option because cardiomyocyte regeneration in the human heart is generally very limited. Today, unfortunately, there is considerably less heart transplantation tissue available than the current need for transplants. Tens of thousands of hearts could be used each year for transplants but only about 2,000 hearts are available. Chemical biology approaches to embryonic stem cell (ESC) research offers considerable promise for rectifying this problem. However, despite progress, increasing the efficiency of stem or progenitor cells to become human cardiomyocytes has been very challenging. The main problem with increasing the yield of cardiomyocytes is the lack of effective ways to induce ESCs to afford cardiomyocytes involved in cardiogenesis. A critical issue is the low yields of cardiomyocytes from in vitro differentiation processes. An economically viable biotechnological process using readily available and inexpensive differentiation agents is needed. Herein, we propose to use a powerful combination of high content and high throughput cellular assays and dynamic medicinal chemistry to develop pure, easy to make, small molecule "toolbox" compounds to promote the induction of hESCs that will differentiate into cardiomyocytes. A promising new cardiomyocyte differentiation agent (i.e., compound 1) has been identified and refinement and development of this agent is the focus of this proposal. The Specific Aims include: 1) Test compounds structurally related to 1 as inducers of cardiomyocytes in a validated mouse ESC assay and 2) Test potent compounds identified in Aim 1 in a validated human ESC assay for cardiomyocyte differentiation. Based on our encouraging Preliminary Results successful completion of the proposed work will provide an inexpensive toolbox of reagents useful for the induction of cardiomyocytes from human ESCs of utility in a biotechnological sense. Preparation of human cardiomyocytes in this manner will provide large numbers of cardiomyocytes and will be of widespread use to the CRO, biotechnology or Big Pharma industry to help individuals that suffer from heart failure including myocardial infarct as well as to do drug safety tests with human cardiomyocytes to decrease adverse drug-drug interactions and develop safer drugs. PUBLIC HEALTH RELEVANCE: For heart attack victims, stem cell therapy may provide a way to regenerate damaged heart muscle cells. Current therapies are only able to improve heart function. The goal of our work is to use chemical biology to develop small molecule "toolbox" compounds that will stimulate stem cell differentiation and produce cardiomyocytes. Ultimately, the results from this work will provide reagents for use to grow cardiomyocytes for use in a biotechnology process to treat heart disease.

描述（由申请人提供）：超过1-2%的65岁以上的美国人患有心脏病。根据美国心脏协会的数据，心力衰竭是西方世界65岁以上患者住院治疗的最常见原因之一，随着人口老龄化，这种情况只会变得更糟。目前，超过500万美国人患有心力衰竭。2009年，美国社会因心脏病造成的经济损失（直接和间接）超过每年370亿美元。某些与心肌衰竭或心肌衰弱有关的疾病可以用药物或设备治疗，如心脏起搏器，心脏起搏器或植入泵。然而，在心脏病发作时，当心肌细胞死亡时，移植成为唯一的选择，因为人类心脏中的心肌细胞再生通常非常有限。今天，不幸的是，有相当少的心脏移植组织比目前需要的移植。每年有数万颗心脏可用于移植，但只有大约2,000颗心脏可用。胚胎干细胞（ESC）研究的化学生物学方法为纠正这一问题提供了相当大的希望。然而，尽管取得了进展，但提高干细胞或祖细胞成为人类心肌细胞的效率一直非常具有挑战性。提高心肌细胞产量的主要问题是缺乏有效的方法来诱导ESCs提供参与心脏发生的心肌细胞。一个关键问题是体外分化过程中心肌细胞的产量低。需要一种经济上可行的生物技术方法，使用容易获得和廉价的分化剂。在此，我们建议使用高含量和高通量细胞测定和动态药物化学的强大组合来开发纯的、易于制造的小分子“工具箱”化合物，以促进将分化成心肌细胞的hESC的诱导。一种有前途的新心肌细胞分化剂（即，化合物1）已经被鉴定，并且该试剂的改进和开发是本建议的重点。具体目标包括：1）在经验证的小鼠ESC测定中作为心肌细胞诱导剂的结构上与1相关的测试化合物和2）在经验证的人ESC测定中测试在目的1中鉴定的有效化合物用于心肌细胞分化。基于我们令人鼓舞的初步结果，所提出的工作的成功完成将提供一个廉价的试剂工具箱，用于从生物技术意义上的实用人类胚胎干细胞诱导心肌细胞。以这种方式制备人心肌细胞将提供大量的心肌细胞，并且将广泛用于CRO、生物技术或大型制药行业，以帮助患有心力衰竭（包括心肌梗死）的个体，以及用人心肌细胞进行药物安全性测试，以减少不良的药物-药物相互作用并开发更安全的药物。 公共卫生相关性：对于心脏病发作的受害者，干细胞疗法可能提供一种再生受损心肌细胞的方法。目前的治疗方法只能改善心脏功能。我们工作的目标是利用化学生物学来开发小分子“工具箱”化合物，这些化合物将刺激干细胞分化并产生心肌细胞。最终，这项工作的结果将提供用于培养心肌细胞的试剂，用于治疗心脏病的生物技术过程。